title: A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma.
abstract: BACKGROUND
  we conducted a multicentre Phase 1b/2 trial to evaluate the safety and efficacy of mapatumumab, a fully human agonistic monoclonal antibody to the tumour necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in patients with relapsed non-Hodgkin's lymphoma (NHL).
  
  
  METHODS
  forty patients with relapsed or refractory NHL were treated with either 3 or 10 mg kg(-1) mapatumumab every 21 days. In the absence of disease progression or prohibitive toxicity, patients received a maximum of six doses.
  
  
  RESULTS
  mapatumumab was well tolerated, with no patients experiencing drug-related hepatic or other dose-limiting toxicity. Three patients with follicular lymphoma (FL) experienced clinical responses, including two with a complete response and one with a partial response. Immunohistochemistry staining of the TRAIL-R1 suggested that strong staining in tumour specimens did not appear to be a requirement for mapatumumab activity in FL.
  
  
  CONCLUSIONS
  mapatumumab is safe and has promising clinical activity in patients with FL.
authors.affiliation: MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA. ayounes@mdanderson.org
authors.forename: A
authors.initials: A
authors.lastname: Younes
authors.forename: J M
authors.initials: JM
authors.lastname: Vose
authors.forename: A D
authors.initials: AD
authors.lastname: Zelenetz
authors.forename: M R
authors.initials: MR
authors.lastname: Smith
authors.forename: H A
authors.initials: HA
authors.lastname: Burris
authors.forename: S M
authors.initials: SM
authors.lastname: Ansell
authors.forename: J
authors.initials: J
authors.lastname: Klein
authors.forename: W
authors.initials: W
authors.lastname: Halpern
authors.forename: R
authors.initials: R
authors.lastname: Miceli
authors.forename: E
authors.initials: E
authors.lastname: Kumm
authors.forename: N L
authors.initials: NL
authors.lastname: Fox
authors.forename: M S
authors.initials: MS
authors.lastname: Czuczman
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000032:analysis / Q000037:antagonists & inhibitors*; D012008:Recurrence
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; C507357:mapatumumab